MA30344B1 - Pyrazoles actifs sur la 11-beta-hsd-1 - Google Patents

Pyrazoles actifs sur la 11-beta-hsd-1

Info

Publication number
MA30344B1
MA30344B1 MA31307A MA31307A MA30344B1 MA 30344 B1 MA30344 B1 MA 30344B1 MA 31307 A MA31307 A MA 31307A MA 31307 A MA31307 A MA 31307A MA 30344 B1 MA30344 B1 MA 30344B1
Authority
MA
Morocco
Prior art keywords
hsd
beta
pyrazoles
active
compounds
Prior art date
Application number
MA31307A
Other languages
English (en)
Inventor
Kevin William Anderson
Nader Fotouhi
Paul Gillespie
Robert Alan Goodnow Jr
Kevin Richard Guertin
Nancy-Ellen Haynes
Michael Paul Myers
Sherrie Lynn Pietranico-Cole
Lida Qi
Pamela Loreen Rossman
Nathan Robert Scott
Kshitij Chhabilbhai Thakkar
Jefferson Wright Tilley
Qiang Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38430507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30344(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30344B1 publication Critical patent/MA30344B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pretreatment Of Seeds And Plants (AREA)

Abstract

Pyrazoles actifs sur la 11-bêta-HSD-l II est proposé ici des composés de formule (I) ainsi que leurs sels pharmaceutiquement acceptables, dans lesquels les substituants sont ceux décrits dans le mémoire descriptif. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies telles que, par exemple, le diabète sucré de type II et le syndrome métabolique.
MA31307A 2006-03-22 2008-10-20 Pyrazoles actifs sur la 11-beta-hsd-1 MA30344B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78483106P 2006-03-22 2006-03-22
US87527406P 2006-12-15 2006-12-15

Publications (1)

Publication Number Publication Date
MA30344B1 true MA30344B1 (fr) 2009-04-01

Family

ID=38430507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31307A MA30344B1 (fr) 2006-03-22 2008-10-20 Pyrazoles actifs sur la 11-beta-hsd-1

Country Status (30)

Country Link
US (1) US7728029B2 (fr)
EP (2) EP2295411A1 (fr)
JP (1) JP5031817B2 (fr)
KR (2) KR101077366B1 (fr)
CN (1) CN101405270B (fr)
AR (1) AR059983A1 (fr)
AU (1) AU2007228887B2 (fr)
BR (1) BRPI0708974A2 (fr)
CA (1) CA2645856C (fr)
CR (1) CR10288A (fr)
DK (1) DK1999114T3 (fr)
EC (1) ECSP088747A (fr)
ES (1) ES2548002T3 (fr)
HK (1) HK1130780A1 (fr)
HR (1) HRP20151078T1 (fr)
HU (1) HUE026011T2 (fr)
IL (1) IL193900A (fr)
MA (1) MA30344B1 (fr)
MX (1) MX2008012017A (fr)
MY (1) MY149622A (fr)
NO (1) NO341746B1 (fr)
NZ (1) NZ570973A (fr)
PL (1) PL1999114T3 (fr)
PT (1) PT1999114E (fr)
RS (1) RS54216B1 (fr)
RU (2) RU2470016C2 (fr)
SG (1) SG155961A1 (fr)
SI (1) SI1999114T1 (fr)
TW (2) TWI351403B (fr)
WO (1) WO2007107470A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
KR101109436B1 (ko) * 2006-11-02 2012-02-06 시오노기세이야쿠가부시키가이샤 히드록시아다만탄아민의 제조 방법
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20100144717A1 (en) * 2006-12-15 2010-06-10 Janelle Comita-Prevoir 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CA2689659C (fr) * 2007-05-18 2012-10-23 Shionogi And Co., Ltd. Derive heterocyclique contenant de l'azote possedant une activite inhibitrice sur la 11.beta.-hydroxysteroide deshydrogenase de type 1
AU2008277783B2 (en) * 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2072497A1 (fr) * 2007-12-21 2009-06-24 Bayer CropScience AG Procédé de fabrication de dérivés de 2-fluoracyl-3-amino acide acrylique
SA109300090B1 (ar) * 2008-02-04 2011-10-03 استرازينيكا ايه بي صور متبلرة جديدة من 4- [4- (2- أدامنتيل كربامويل) -5- ثلاثي- بيوتيل – بيرازول -1- يل] حمض بنزويك 471
JP2012516327A (ja) * 2009-01-30 2012-07-19 アストラゼネカ アクチボラグ カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
EP2243479A3 (fr) 2009-04-20 2011-01-19 Abbott Laboratories Nouvel amide et dérivés d'amidine et utilisations associées
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
JP5686413B2 (ja) * 2009-12-22 2015-03-18 塩野義製薬株式会社 アダマンタンアミン誘導体
CN102127583A (zh) * 2010-01-19 2011-07-20 上海博康精细化工有限公司 一种反式对氨基金刚烷醇的制备方法
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8901316B2 (en) 2010-08-09 2014-12-02 Shionogi & Co., Ltd. Process for preparing aminoadamantyl carbamate derivatives
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2012176717A1 (fr) 2011-06-22 2012-12-27 セントラル硝子株式会社 Procédé de fabrication d'un composé pyrazole
JP2013023476A (ja) * 2011-07-22 2013-02-04 Sagami Chemical Research Institute ５−フルオロ−１ｈ−ピラゾール−４−カルボン酸類の製造方法
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
EP2785698B1 (fr) 2011-11-30 2018-10-10 Bayer Intellectual Property GmbH Dérivés (n-bicycloakyl et n-tricycloalkyl)(thio)carboxamides fongicides
CN102633659B (zh) * 2012-02-23 2013-12-04 浙江普洛康裕制药有限公司 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法
BR112015018311B1 (pt) 2013-02-06 2021-01-05 Bayer Animal Health Gmbh compostos derivados de pirazol substituídos por halogêneo como agentes de controle de pragas, composição farmacêutica e uso dos mesmos, processo para a preparação de composições de proteção de colheitas e método para o controle de pragas
US10184499B2 (en) 2013-07-24 2019-01-22 Volvo Construction Equipment Ab Hydraulic circuit for construction machine
BR112016011890B1 (pt) * 2013-11-27 2021-11-16 Bayer Animal Health Gmbh Processo para preparação de 5-fluoro-1h-pirazóis
MX2016006977A (es) 2013-11-27 2016-09-07 Bayer Cropscience Ag Proceso para la preparacion de 5-fluoro-1h-pirazoles.
MX2016008653A (es) 2014-01-03 2016-09-26 Bayer Animal Health Gmbh Nuevas pirazolil-heteroarilamidas como agentes plaguicidas.
CN105315284A (zh) * 2014-07-23 2016-02-10 上海医药工业研究院 阿拉格列汀中间体的制备方法
CN104961698A (zh) * 2015-07-13 2015-10-07 佛山市赛维斯医药科技有限公司 末端硝基取代的三氮唑亚砜类化合物、其制备方法及其用途
KR101759874B1 (ko) * 2015-08-07 2017-07-21 코스맥스 주식회사 11β-hydroxysteroid dehydrogenase type 1의 활성을 저해하는 화합물을 포함하는 화장료 조성물 또는 피부 외용제 조성물
AR118994A1 (es) * 2019-05-24 2021-11-17 Fmc Corp Pirrilidinonas de pirazol sustituido como herbicidas

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH307629A (de) 1952-05-23 1955-06-15 Ag J R Geigy Verfahren zur Herstellung eines monosubstituierten Hydrazins.
DE2635841C2 (de) 1976-08-10 1983-02-24 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von Alkoxymethylenmalonsäurenitrilen
US4620865A (en) 1983-11-07 1986-11-04 Eli Lilly And Company Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides
KR920003893B1 (ko) 1984-10-29 1992-05-18 스미또모가가꾸고오교 가부시끼가이샤 피라졸 카르복스아미드 유도체의 제조방법
US4792565A (en) 1986-04-24 1988-12-20 Mitsui Toatsu Chemicals, Inc. Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US6020121A (en) 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
DE19615976A1 (de) 1996-04-22 1997-10-23 Basf Ag Mittel und Verfahren zur Bekämpfung von Schadpilzen
CA2283797A1 (fr) 1997-03-18 1998-09-24 Paul Elliot Bender Nouveaux agonistes de recepteurs de cannabinoides
DK1201128T3 (da) 1997-12-18 2006-01-30 Basf Ag Fungicide blandinger på basis af amidforbindelser og morpholin- eller piperidinderivater
WO1999067235A1 (fr) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Co., Ltd. Composes cycliques a cinq elements
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19853827A1 (de) 1998-11-21 2000-05-25 Aventis Cropscience Gmbh Kombinationen aus Herbiziden und Safenern
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL136360A (en) 1999-06-18 2004-08-31 Mitsui Chemicals Inc History 5 - Aminopyrazole-4 - Carboxylate and processes for their preparation
CN1208321C (zh) 1999-07-20 2005-06-29 道农业科学公司 杀真菌的杂环芳族酰胺和它们的组合物、使用方法和制备
BR0013469B1 (pt) 1999-08-20 2011-01-25 amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica.
EP1224173B1 (fr) 1999-10-18 2005-10-12 The University Of Connecticut Derives de pyrazole comme antagonistes des recepteurs des cannabinoides
US6096898A (en) 1999-10-22 2000-08-01 Dow Agrosciences Llc One pot synthesis of 1,2,4-triazoles
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP2002003410A (ja) 2000-06-27 2002-01-09 Fuji Photo Film Co Ltd 芳香族ハロゲン化物の製造方法。
AU2002210839A1 (en) 2000-11-28 2002-06-11 Pfizer Products Inc. Preparation of sodium-hydrogen exchanger type-1 inhibitors
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
CN1582281A (zh) 2001-10-01 2005-02-16 大正制药株式会社 Mch受体拮抗剂
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
DE10161978A1 (de) 2001-12-17 2003-06-26 Bayer Ag Verfahren zur Herstellung von 2-Halogenacyl-3-amino-acrylsäure-derivate
WO2003051845A1 (fr) 2001-12-19 2003-06-26 Pfizer Products Inc. Methodes de preparation d'inhibiteurs de type 1 d'echangeurs de sodium-hydrogene
WO2003070244A1 (fr) 2002-02-22 2003-08-28 Abbott Laboratories Antagoniste des effets d'une hormone de concentration de melanine et son utilisation
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1388535A1 (fr) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Arylcycloalkylamines acylés et leurs utilisations comme produits pharmaceutiques
JP2005535710A (ja) 2002-08-09 2005-11-24 トランス　テック　ファーマ，インコーポレイテッド アリールおよびヘテロアリール化合物ならびに凝固を調節する方法
RU2360910C2 (ru) * 2002-12-20 2009-07-10 Мерк Энд Ко., Инк. Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1
ES2271844T3 (es) 2003-02-17 2007-04-16 F. Hoffmann-La Roche Ag Derivados de piperidina-bencenosulfonamida.
WO2004089416A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
WO2004089896A1 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Composes actifs de la 11?-hydroxysteroide deshydrogenase de type 1
WO2004089415A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
SI2298743T1 (sl) 2003-06-26 2012-12-31 Novartis Ag Inhibitorji p38-kinaze na osnovi 5-ÄŤlenskih heterociklov
WO2005000793A1 (fr) 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. Derive d'acide cycloalkylcarboxylique substitue en position 2
CA2534221A1 (fr) 2003-08-07 2005-02-24 Merck & Co., Inc. Carboxamides de pyrazole utilises comme inhibiteurs de la dehydrogenase-1 11-beta-hydroxysteroide
CA2535265C (fr) 2003-08-22 2014-01-28 Dendreon Corporation Compositions et methodes permettant de traiter une maladie associee a l'expression de trp-p8
US20050171171A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
CN101906053B (zh) 2004-01-28 2012-11-21 三井化学株式会社 酰胺衍生物
AU2005227997A1 (en) 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
DE102004023635A1 (de) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
WO2006007864A1 (fr) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Traitement d'etats neurodegeneratifs
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
WO2006031806A2 (fr) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones utilises en tant qu'agents therapeutiques
US20080090863A1 (en) 2004-09-30 2008-04-17 Taisho Pharmaceutical Co., Ltd. Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
WO2006106052A1 (fr) * 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag 1h-pyrazole 4-carboxylamides, preparation et utilisation de ceux-ci comme 11-beta-hydroxysteroide deshydrogenase
RU2443689C2 (ru) * 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА

Also Published As

Publication number Publication date
RU2402517C2 (ru) 2010-10-27
CA2645856C (fr) 2011-09-20
TW201103916A (en) 2011-02-01
JP2009530343A (ja) 2009-08-27
SG155961A1 (en) 2009-10-29
CA2645856A1 (fr) 2007-09-27
RU2470016C2 (ru) 2012-12-20
AR059983A1 (es) 2008-05-14
TWI351403B (en) 2011-11-01
EP2295411A1 (fr) 2011-03-16
NZ570973A (en) 2011-11-25
IL193900A (en) 2013-08-29
TW200806651A (en) 2008-02-01
WO2007107470A3 (fr) 2007-11-08
US20070225280A1 (en) 2007-09-27
PL1999114T3 (pl) 2015-12-31
ECSP088747A (es) 2008-10-31
SI1999114T1 (sl) 2015-10-30
AU2007228887B2 (en) 2012-02-02
MX2008012017A (es) 2008-10-01
AU2007228887A1 (en) 2007-09-27
JP5031817B2 (ja) 2012-09-26
HUE026011T2 (en) 2016-05-30
US7728029B2 (en) 2010-06-01
CN101405270B (zh) 2013-01-16
PT1999114E (pt) 2015-10-16
HRP20151078T1 (hr) 2015-11-20
MY149622A (en) 2013-09-13
WO2007107470A2 (fr) 2007-09-27
RU2010119648A (ru) 2011-11-27
KR101077366B1 (ko) 2011-10-26
EP1999114A2 (fr) 2008-12-10
NO20083863L (no) 2008-12-03
KR20090005015A (ko) 2009-01-12
BRPI0708974A2 (pt) 2011-06-21
KR20110007258A (ko) 2011-01-21
EP1999114B1 (fr) 2015-07-22
ES2548002T3 (es) 2015-10-13
CR10288A (es) 2008-10-06
RU2008141434A (ru) 2010-04-27
DK1999114T3 (en) 2015-08-03
CN101405270A (zh) 2009-04-08
HK1130780A1 (en) 2010-01-08
RS54216B1 (en) 2015-12-31
NO341746B1 (no) 2018-01-15

Similar Documents

Publication Publication Date Title
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20070155L (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
TW200643013A (en) Pyrazoles
TNSN08194A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
MA29909B1 (fr) Derives de pyridazine
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
BRPI1008727B8 (pt) derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
DE602008003404D1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.